NASDAQ : DERM
Journey Medical Corporation — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 5.17 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 145.92M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 142.82M |
| Enterprise Value | 142.71M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 22.22M |
| Shares Outstanding | 28.22M |
| Shares Change (YoY) | +21.63% |
| Shares Change (QoQ) | +0.69% |
| Owned by Insiders (%) | 11.59% |
| Owned by Institutions (%) | 36.22% |
| Float | 15.59M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 46.00 |
| PS Ratio | 2.14 |
| Forward PS | 1.51 |
| PB Ratio | 4.45 |
| P/TBV Ratio | 22.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 2.14 |
| EV / EBITDA | 119.92 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.59 |
| Quick Ratio | 1.35 |
| Debt / Equity | 0.80 |
| Debt / EBITDA | 19.32 |
| Debt / FCF | n/a |
| Interest Coverage | -0.82 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -23.77% |
| Return on Assets (ROA) | -2.09% |
| Return on Invested Capital (ROIC) | -9.85% |
| Return on Capital Employed (ROCE) | -5.72% |
| Weighted Average Cost of Capital (WACC) | 10.51% |
| Revenue Per Employee | $1.18M |
| Profits Per Employee | -$105,241 |
| Employee Count | 58 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 2.24 |
Taxes
| Measure | Value |
|---|
| Income Tax | 15,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.11 |
| 52-Week Price Change | -35.71% |
| 50-Day Moving Average | 6.47 |
| 200-Day Moving Average | 6.63 |
| Relative Strength Index (RSI) | 41.59 |
| Average Volume (20 Days) | 199,686 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.99M |
| Short Previous Month | 3.06M |
| Short % of Shares Out | 10.59% |
| Short % of Float | 19.16% |
| Short Ratio (days to cover) | 14.92 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 68.18M |
| Gross Profit | 44.63M |
| Operating Income | -3.01M |
| Pretax Income | -6.09M |
| Net Income | -6.10M |
| EBITDA | 1.22M |
| EBIT | -3.01M |
| Loss Per Share | -$0.23 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 25.64M |
| Total Debt | 25.54M |
| Net Cash | 102,000 |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | 32.11M |
| Book Value Per Share | 1.16 |
| Working Capital | 27.01M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -7.49M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 4.22M |
| Net Borrowing | n/a |
| Free Cash Flow | -7.49M |
| FCF Per Share | -$0.27 |
Margins
| Measure | Value |
|---|
| Gross Margin | 65.45% |
| Operating Margin | -4.41% |
| Pretax Margin | -8.93% |
| Profit Margin | -8.95% |
| EBITDA Margin | 1.78% |
| EBIT Margin | -4.41% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -21.63% |
| Shareholder Yield | -21.63% |
| Earnings Yield | -4.51% |
| FCF Yield | -5.13% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $13.75 |
| Price Target Difference | 171.74% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 37.17% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.19 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |